Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis

Oncogene

Volumn 33, Issue 16, 2014, Pages 2134-2144

  Hill, K S ^a   Erdogan, E ^a   Khoor, A ^a   Walsh, M P ^a   Leitges, M ^b   Murray, N R ^a   Fields, A P ^a  

^a MAYO CLINIC   (United States)

^b Biotechnology Centre of Oslo   (Norway)

Author keywords

bronchio alveolar stem cells; inhibitors of DNA Binding (Id); lung adenocarcinoma; p38 MAPK; tumor suppressor; Wilm's Tumor 1 gene

Indexed keywords

ANIMALS; BRONCHIOLES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF DIFFERENTIATION PROTEINS; LUNG NEOPLASMS; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE C-ALPHA; PROTO-ONCOGENE PROTEINS P21(RAS); PULMONARY ALVEOLI; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STEM CELLS; TRANSFORMING GROWTH FACTOR BETA; WT1 PROTEINS;

EID: 84899408283     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.147     Document Type: Article

References (64)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29
2. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y. Direct activation of calcium-Activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 1982; 257: 7847-7851
3. Kikkawa U, Takai Y, Tanaka Y, Miyake R, Nishizuka Y. Protein kinase C as a possible receptor protein of tumor-promoting phorbol esters. J Biol Chem 1983; 258: 11442-11445
4. Fields AP, Murray NR. Protein kinase C isozymes as therapeutic targets for treatment of human cancers. Adv Enzyme Regul 2008; 48: 166-178
5. Cacace AM, Ueffing M, Philipp A, Han EK, Kolch W, Weinstein IB. PKC epsilon functions as an oncogene by enhancing activation of the Raf kinase. Oncogene 1996; 13: 2517-2526
6. Mischak H, Goodnight JA, Kolch W, Martiny-Baron G, Schaechtle C, Kazanietz MG, et al. Overexpression of protein kinase C-delta and-epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. J Biol Chem 1993; 268: 6090-6096
7. Reddig PJ, Dreckschmidt NE, Ahrens H, Simsiman R, Tseng CP, Zou J, et al. Transgenic mice overexpressing protein kinase Cdelta in the epidermis are resistant to skin tumor promotion by 12-O-Tetradecanoylphorbol-13-Acetate. Cancer Res 1999; 59: 5710-5718
8. Reddig PJ, Dreckschmidt NE, Zou J, Bourguignon SE, Oberley TD, Verma AK. Transgenic mice overexpressing protein kinase C epsilon in their epidermis exhibit reduced papilloma burden but enhanced carcinoma formation after tumor promotion. Cancer Res 2000; 60: 595-602
9. Fields AP, Frederick LA, Regala RP. Targeting the oncogenic protein kinase Ciota signalling pathway for the treatment of cancer. Biochem Soc Trans 2007; 35(Pt 5): 996-1000
10. Justilien V, Fields A. Atypical PKCs as targets for cancer therapy. In: Kazanietz M eds. Protein Kinase C in Cancer Signaling and Therapy. Springer: London, 2010
11. Regala RP, Weems C, Jamieson L, Khoor A, Edell ES, Lohse CM, et al. Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res 2005; 65: 8905-8911
12. Regala RP, Weems C, Jamieson L, Copland JA, Thompson EA, Fields AP. Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J Biol Chem 2005; 280: 31109-31115
13. Regala RP, Davis RK, Kunz A, Khoor A, Leitges M, Fields AP. Atypical protein kinase Ci is required for bronchioalveolar stem cell expansion and lung tumorigenesis. Cancer Res 2009; 69: 7603-7611
14. Murray NR, Jamieson L, Yu W, Zhang J, Gokmen-Polar Y, Sier D, et al. Protein kinase Ciota is required for Ras transformation and colon carcinogenesis in vivo. J Cell Biol 2004; 164: 797-802
15. Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP, et al. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 12519-12524
16. Zhang L, Huang J, Yang N, Liang S, Barchetti A, Giannakakis A, et al. Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res 2006; 66: 4627-4635
17. Jamieson L, Carpenter L, Biden TJ, Fields AP. Protein kinase Ciota activity is necessary for Bcr-Abl-mediated resistance to drug-induced apoptosis. J Biol Chem 1999; 274: 3927-3930
18. Murray NR, Fields AP. Atypical protein kinase Ciota protects human leukemia cells against drug-induced apoptosis. J Biol Chem 1997; 272: 27521-27524
19. Scotti ML, Bamlet WR, Smyrk TC, Fields AP, Murray NR. Protein kinase Ci is required for pancreatic cancer cell transformed growth and tumorigenesis. Cancer Res 2010; 70: 2064-2074
20. Scotti ML, Smith KE, Butler AM, Calcagno SR, Crawford HC, Leitges M, et al. Protein kinase Ciota regulates pancreatic acinar-To-ductal metaplasia. PLoS One 2012; 7: E30509
21. Kikuchi K, Soundararajan A, Zarzabal LA, Weems CR, Nelon LD, Hampton ST, et al. Protein kinase Ciota as a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 2013; 32: 286-295
22. Erdogan E, Lamark T, Stallings-Mann M, Lee J, Pellecchia M, Thompson EA, et al. Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Ciota. J Biol Chem 2006; 281: 28450-28459
23. Stallings-Mann M, Jamieson L, Regala RP, Weems C, Murray NR, Fields AP. A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells. Cancer Res 2006; 66: 1767-1774
24. Nazarenko I, Jenny M, Keil J, Gieseler C, Weisshaupt K, Sehouli J, et al. Atypical protein kinase C zeta exhibits a proapoptotic function in ovarian cancer. Mol Cancer Res 2010; 8: 919-934
25. Galvez AS, Duran A, Linares JF, Pathrose P, Castilla EA, Abu-Baker S, et al. Protein kinase Czeta represses the interleukin-6 promoter and impairs tumorigenesis in vivo. Mol Cell Biol 2009; 29: 104-115
26. Hsieh YH, Wu TT, Huang CY, Hsieh YS, Hwang JM, Liu JY. p38 mitogen-Activated protein kinase pathway is involved in protein kinase Calpha-regulated invasion in human hepatocellular carcinoma cells. Cancer Res 2007; 67: 4320-4327
27. Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, Kazanietz MG. Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem 2003; 278: 33753-33762
28. Oster H, Leitges M. Protein kinase C alpha but not PKCzeta suppresses intestinal tumor formation in ApcMin/ mice. Cancer Res 2006; 66: 6955-6963
29. Oliva JL, Caino MC, Senderowicz AM, Kazanietz MG. S-phase-specific activation of PKCa induces senescence in non-small cell lung cancer cells. J Biol Chem 2008; 283: 5466-5476
30. Nakagawa M, Oliva JL, Kothapalli D, Fournier A, Assoian RK, Kazanietz MG. Phorbol ester-induced G1 phase arrest selectively mediated by protein kinase Cdelta-dependent induction of p21. J Biol Chem 2005; 280: 33926-33934
31. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243-3248
32. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001; 410: 1111-1116
33. Nikitin AY, Alcaraz A, Anver MR, Bronson RT, Cardiff RD, Dixon D, et al. Classification of proliferative pulmonary lesions of the mouse: Recommendations of the mouse models of human cancers consortium. Cancer Res 2004; 64: 2307-2316
34. Collado M, Serrano M. Senescence in tumours: Evidence from mice and humans. Nat Rev Cancer 2010; 10: 51-57
35. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88: 593-602
36. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005; 121: 823-835
37. Iwasa H, Han J, Ishikawa F. Mitogen-Activated protein kinase p38 defines the common senescence-signalling pathway. Genes Cells 2003; 8: 131-144
38. Wang W, Chen JX, Liao R, Deng Q, Zhou JJ, Huang S, et al. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-Activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 2002; 22: 3389-3403
39. Ventura JJ, Tenbaum S, Perdiguero E, Huth M, Guerra C, Barbacid M, et al. p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet 2007; 39: 750-758
40. Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 2003; 4: 657-665
41. Hao F, Pysz MA, Curry KJ, Haas KN, Seedhouse SJ, Black AR, et al. Protein kinase Calpha signaling regulates inhibitor of DNA binding 1 in the intestinal epithelium. J Biol Chem 2011; 286: 18104-18117
42. Pysz MA, Leontieva OV, Bateman NW, Uronis JM, Curry KJ, Threadgill DW, et al. PKCa tumor suppression in the intestine is associated with transcriptional and translational inhibition of cyclin D1. Exp Cell Res 2009; 315: 1415-1428
43. Vicent S, Chen R, Sayles LC, Lin C, Walker RG, Gillespie AK, et al. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest 2010; 120: 3940-3952
44. Fields AP, Gustafson WC. Protein kinase C in disease: Cancer. Methods Mol Biol 2003; 233: 519-537
45. Bivona TG, Quatela SE, Bodemann BO, Ahearn IM, Soskis MJ, Mor A, et al. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol Cell 2006; 21: 481-493
46. Tossidou I, Starker G, Kruger J, Meier M, Leitges M, Haller H, et al. PKC-Alpha modulates TGF-beta signaling and impairs podocyte survival. Cell Physiol Biochem 2009; 24: 627-634
47. Lindschau C, Quass P, Menne J, Guler F, Fiebeler A, Leitges M, et al. Glucose-induced TGF-beta1 and TGF-beta receptor-1 expression in vascular smooth muscle cells is mediated by protein kinase C-Alpha. Hypertension 2003; 42: 335-341
48. Luo X, Ding L, Xu J, Chegini N. Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta. Endocrinology 2005; 146: 1097-1118
49. Dean N, McKay R, Miraglia L, Howard R, Cooper S, Giddings J, et al. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-Alpha expression. Cancer Res 1996; 56: 3499-3507
50. Geiger T, Muller M, Dean NM, Fabbro D. Antitumor activity of a PKC-Alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des 1998; 13: 35-45
51. Advani R, Peethambaram P, Lum BL, Fisher GA, Hartmann L, Long HJ, et al. A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer 2004; 100: 321-326
52. Grossman SA, Alavi JB, Supko JG, Carson KA, Priet R, Dorr FA, et al. Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-Alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. Neuro Oncol 2005; 7: 32-40
53. Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM, et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-Alpha antisense oligonucleotide, in patients with advanced-stage nonsmall-cell lung cancer. J Clin Oncol 2006; 24: 1428-1434
54. Dalgaard P. Introductory Statistics with R. 2nd edition, (ed) Springer: New York, 2008
55. Smyth GK. Limma: Linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor. In: Gentleman R., Carey V., Dudoit S., Irizarry R., Huber W (eds). Springer: New York, pp 397-420
56. Sanchez-Palencia A, Gomez-Morales M, Gomez-Capilla JA, Pedraza V, Boyero L, Rosell R, et al. Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer. Int J Cancer 2011; 129: 355-364
57. Hou J, Aerts J, Den Hamer B, van Ijcken W, Den Bakker M, Riegman P, et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One 2010; 5: E10312
58. Dehan E, Ben-Dor A, Liao W, Lipson D, Frimer H, Rienstein S, et al. Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. Lung Cancer 2007; 56: 175-184
59. Leitges M, Plomann M, Standaert ML, Bandyopadhyay G, Sajan MP, Kanoh Y, et al. Knockout of PKC alpha enhances insulin signaling through PI3K. Mol Endocrinol 2002; 16: 847-858
60. Fasbender A, Lee JH, Walters RW, Moninger TO, Zabner J, Welsh MJ. Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo. J Clin Invest 1998; 102: 184-193
61. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004; 5: 375-387
62. Malkinson AM, Nesbitt MN, Skamene E. Susceptibility to urethan-induced pulmonary adenomas between A/J and C57BL/6J mice: Use of AXB and BXA recombinant inbred lines indicating a three-locus genetic model. J Natl Cancer Inst 1985; 75: 971-974
63. Regala R, Justilien V, Walsh MP, Weems C, Khoor A, Murray NR, et al. Matrix metalloproteinase-10 promotes kras-mediated bronchio-Alveolar stem cell expansion and lung cancer formation. PLoS One 2011; 6: E26439
64. Yang Y, Iwanaga K, Raso MG, Wislez M, Hanna AE, Wieder ED, et al. Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS One 2008; 3: E2220